4.30
-7.53%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Prime Medicine
From its filings with the US Securities and Exchange Commission
Prime Medicine is based in Cambridge, Massachusetts and is incorporated in Delaware. Its shares trade on Nasdaq under the ticker PRME. The SEC classifies its business as biological products, (no diagnostic substances). In the fiscal year to 31 December 2025, it reported revenue of $4.6m and a net loss of $201.1m. At that date it held total assets of $342.7m and shareholders' equity of $120.9m.
We are a biotechnology company focused on developing a new class of genetic medicines designed to provide durable, and potentially curative, treatment options for patients with diseases driven by defined genetic alterations, acquired cellular dysfunction, or dysregulated gene expression. Our approach is grounded in Prime Editing, a next-generation gene editing technology that enables targeted modifications to genomic DNA without introducing double-stranded breaks. We believe Prime Editing represents the most versatile and precise method for rewriting, replacing, or repairing DNA sequences and may allow us to address a broad spectrum of diseases with an improved safety and specificity profile relative to earlier editing technologies. We are advancing a pipeline of wholly owned in vivo programs targeting diseases of the liver, Cystic Fibrosis, or CF, programs with the support of the Cystic Fibrosis Foundation, or CFF, and partnered ex vivo programs with Bristol-Myers Squibb, or BMS, supported by our modular delivery and Prime Editor platform. Early clinical data from our ex vivo program, PM359 for CGD, have demonstrated restoration of functional protein activity in treated patients, providing clinical validation of Prime Editing and a potentially curative treatment for CGD patients.
Quoted from its 10-K, filed 3 Mar 2026. Read the filing on SEC.gov ↗
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 20 Oct 2022
- Employees
- 146
- Website
- primemedicine.com ↗
- Head office
- 60 FIRST ST., CAMBRIDGE, MA, 02141
- Incorporated in
- DE
- Classification
- Biological Products, (No Diagnostic Substances)
- Filer status
- Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
Leadership
Pay as last reported
- Mr. Jeffrey MarrazzoExecutive Chairman of the Board, since 2023$1.8m
- Dr. Allan ReineChief Executive Officer, Chief Financial Officer, Director, since 2024$4.6m
- Dr. Andrew AnzaloneCo-Founder, Head of Prime Editing Platform
- Dr. Meredith GoldwasserSenior Vice President - Strategy and Corporate Operations
- Dr. Ann LeeChief Technical Officer$2.3m
- Mr. Richard BrudnickChief Business Officer$1.4m
- Dr. Thomas CahillIndependent Director$294,716
- Dr. Wendy ChungIndependent Director$294,716
- Ms. Kaye FosterIndependent Director$294,528
- Mr. Michael KellyIndependent Director$298,778
- Mr. Robert NelsenIndependent Director$287,591
- Dr. David SchenkeinIndependent Director$297,591
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 44
- Environment
- 47
- Social
- 47
- Governance
- 37
- Carbon reduction policy
- No
- Human rights policy
- No
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Prime Medicine's prime editing platform enables precise genetic therapies with minimal DNA modifications.
- The company employs 146 full-time employees focused on developing one-time curative treatments.
- Prime Medicine has 18 genetic disease programs targeting various tissues and organs.
Weaknesses
- Prime Medicine's IPO occurred in 2022, limiting its market experience.
- The company has a small employee count of 146 compared to industry peers.
- Prime Medicine's focus on genetic therapies may restrict its market diversification.
Opportunities
- Prime Medicine's prime editing technology can address a wide range of genetic mutations across multiple tissues.
- The growing biotechnology sector in the US offers expansion potential for genetic therapies.
- Prime Medicine's 18 programs provide a diversified portfolio for future market growth.
Threats
- Prime Medicine faces competition from established biotech firms in the US market.
- Regulatory challenges may delay the approval of genetic therapies in the US.
- The high costs of developing one-time curative genetic therapies could limit market adoption.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.